Concepedia

Anthony Tolcher

AT

Statistics

Publications

9

Citations

332

H-Index

9

Active since

2001

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

Sarah Cannon

Anthony Tolcher is an author at The University of Texas at San Antonio Health Science Center specializing in oncology, medicine, and pharmacology.

Publications per year

2001–2021

9

Publications

9

Preliminary phase I results of G3139 (-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

Anthony Tolcher · Seminars in Oncology · 2001 · 79 citations

, , +12

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Monica Mita, Kevin R. Kelly, Alain C. Mita et al. · Clinical Cancer Research · 2011 · 71 citations

, , +14

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

M. Beeram, Ian E. Krop, Shanu Modi et al. · Journal of Clinical Oncology · 2007 · 40 citations

, , +17

O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies

Sarina A. Piha‐Paul, Johanna C. Bendell, Anthony Tolcher et al. · Oral Presentations · 2020 · 34 citations · Full text

, , +17

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Amita Patnaik, S. Gail Eckhardt, Elżbieta Izbicka et al. · PubMed · 2003 · 33 citations

, , +10

1–5 of 9